Concentric Analgesics, a clinical biopharmaceutical company announced that one of their nonopioid therapeutics, Vocacapsaicin, had passed pilot phase 2 of their clinical trial on patients who have undergone hernia or other abdominal wall surgery.
Hernias are a painful condition where a part of an internal organ bulges out of a weak part of the abdominal wall causing bulging and pain. While surgery is an effective treatment, patients may suffer from pain and a lack of mobility after surgical treatment.
In their study, Vocacapsaicin was administered as a single dose after a ventral hernia repair or laparotomy surgery. In their study of 24 patients, patients reported less pain while coughing (46% less) or walking (35% less) compared to their placebo counterparts. Even better these patients reported that these effects lasted more than 7 days after the initial dose was administered.
This is great news for patients looking for pain relief after any surgery, but not willing to risk developing an attachment to opioid-based pain relievers. Opioid addiction or misuse affected 10.1 million people in 2019, and while numbers are trending downward, treatments like this are a great sign for the over 15 million people who have some sort of surgery every year.
For patients who were looking to have surgery performed, but are unsure about post-surgery pain management, pharmaceuticals like these could prove to be a great option.
If you or a loved one have questions about hernia surgery and post-surgery pain management, consult a medical professional today.